ストックスクリーナーアプリを入手
0.99
2.94%
-0.03
アフターアワーズ：
1.00
0.01
+1.01%
前日終値:
$1.02
開ける：
$1.02
24時間の取引高:
1.59M
Relative Volume:
0.73
時価総額：
$226.07M
収益：
$8.95M
当期純損益:
$-21.49M
株価収益率:
-8.25
EPS:
-0.12
ネットキャッシュフロー:
$-29.24M
1週間 パフォーマンス:
-2.94%
1か月 パフォーマンス:
+15.33%
6か月 パフォーマンス:
+68.54%
1年 パフォーマンス:
-6.60%
1日の値動き範囲:
$0.99
$1.0475
1週間の範囲:
$0.99
$1.12
52週間の値動き範囲:
$0.3651
$1.15
Lineage Cell Therapeutics Inc Stock (LCTX) Company Profile
名前
Lineage Cell Therapeutics Inc
セクター
電話
510-871-4188
住所
2173 Salk Avenue, Suite 200, Carlsbad, CA
LCTX を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
LCTX
Lineage Cell Therapeutics Inc
|
0.99 | 232.92M | 8.95M | -21.49M | -29.24M | -0.12 |
|
VRTX
Vertex Pharmaceuticals Inc
|
463.27 | 123.14B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
550.00 | 60.43B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
324.69 | 42.07B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
572.71 | 34.47B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
290.35 | 27.42B | 3.81B | -644.79M | -669.77M | -6.24 |
Lineage Cell Therapeutics Inc Stock (LCTX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-08-20 | 開始されました | Craig Hallum | Buy |
| 2022-11-02 | 開始されました | Robert W. Baird | Outperform |
| 2022-06-14 | 開始されました | B. Riley Securities | Buy |
| 2021-08-19 | 開始されました | Noble Capital Markets | Outperform |
| 2021-03-31 | 開始されました | Cantor Fitzgerald | Overweight |
Lineage Cell Therapeutics Inc (LCTX) 最新ニュース
Stem Cell Therapy Market Attracts Investment in Neuro, Onco & - openPR.com
What makes Lineage Cell Therapeutics Inc. stock price move sharplyFree Stock Market Practical Discussion Forums - Newser
Why Lineage Cell Therapeutics Inc. stock attracts strong analyst attentionConsistent High Return Strategy - Newser
How Lineage Cell Therapeutics Inc. stock performs during market volatilityFree Stock Index Interpretation - Newser
Cell Therapy Manufacturing Market Exclusive Report with - openPR.com
Cell Therapy Manufacturing Market In-depth Insights, Business - openPR.com
Lineage Cell Therapeutics shareholders approve board slate and equity plan amendment - Investing.com
Lineage Cell Therapeutics unveils promising Phase I/IIa OpRegen results at CTS 2025 - Yahoo Finance
Lineage Cell Therapeutics (LCTX): Analyst Reiterates Buy Rating | LCTX Stock News - GuruFocus
Two Sigma Investments LP Buys New Shares in Lineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX) - Defense World
Rising Demand in Allogeneic Stem Cells Market USD 2.0Bn By 2031 - openPR.com
Squarepoint Ops LLC Takes $46,000 Position in Lineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX) - Defense World
Cell Therapy Manufacturing Market Exclusive Report with Detailed Study Analysis | WuXi AppTec, Healios Ltd. - newstrail.com
Lineage Cell Therapeutics appoints new auditor - Investing.com Australia
Two Sigma Advisers LP Has $44,000 Holdings in Lineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX) - Defense World
Jane Street Group LLC Buys 142,965 Shares of Lineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX) - Defense World
Lineage Cell Therapeutics Announces Updates to the 3rd Annual Spinal Cord Injury Investor Symposium - BioSpace
Deutsche Bank AG Has $87,000 Stock Position in Lineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX) - Defense World
Future of Personalized Treatment: Stem Cell Therapy Market - openPR.com
B. Riley Predicts Lineage Cell Therapeutics FY2029 Earnings - Defense World
Transcript : Lineage Cell Therapeutics, Inc. Presents at H.C. Wainwright 3rd Annual BioConnect Investor Conference 2025, May-20-2025 02 - marketscreener.com
Spinal cord injury Pipeline 2025: Groundbreaking Clinical - openPR.com
Cell Therapy Manufacturing Market Is Booming Worldwide | WuXi - openPR.com
Lineage Cell Therapeutics Q2 EPS Lowered by HC Wainwright - Defense World
Lineage Cell Therapeutics outlines manufacturing milestone and anticipates OpRegen 36-month data update while advancing OPC1 clinical plans - MSN
Comerica Bank Boosts Position in Lineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX) - Defense World
Lineage Cell Therapeutics’ Earnings Call Highlights Progress and Challenges - TipRanks
Barclays PLC Acquires 22,769 Shares of Lineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX) - Defense World
Lineage to Present at 3rd Annual H.C. Wainwright BioConnect Inve - GuruFocus
Lineage Cell Therapeutics Q1 2025 Earnings: EPS Beats Estimates at -$0.02, Revenue Misses at $1.5 Million - GuruFocus
Lineage Cell Therapeutics, Inc. (AMEX:LCTX) Q1 2025 Earnings Call Transcript - Insider Monkey
Lineage to Present at 3rd Annual H.C. Wainwright BioConnect Investor Conference at Nasdaq NYC - Business Wire
Wells Fargo & Company MN Increases Stake in Lineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX) - Defense World
Lineage Cell Therapeutics Inc (LCTX) Q1 2025 Earnings Call Highlights: Strategic Advances and ... - Yahoo Finance
Lineage Cell Therapeutics Reports Q1 2025 Financials - TipRanks
Lineage Cell: Q1 Earnings Snapshot - Huron Daily Tribune
Lineage Cell Therapeutics earnings beat, revenue fell short of estimates By Investing.com - Investing.com Nigeria
Lineage Cell (LCTX) Reports Q1 Loss, Lags Revenue Estimates - Nasdaq
Lineage Cell Therapeutics Reports First Quarter 2025 Financial Results And Provides Business Update - marketscreener.com
Lineage Cell Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update - Business Wire
Examining the Future: Lineage Cell Therapeutics's Earnings Outlook - Nasdaq
RG6501 (OpRegen®) Phase 1/2a Clinical Study 36 Month Results to Be Featured at Clinical Trials at the Summit 2025 - Business Wire
Lineage Cell Therapeutics Inc (LCTX) 財務データ
収益
当期純利益
現金流量
EPS
0.64%
0.37%
大文字化:
|
ボリューム (24 時間):